Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus gasseri + Lactobacillus crispatus is a combination of two key commensal bacterial species used as a live biotherapeutic product (LBP) to support and restore the human vaginal and gastrointestinal microbiota. These Gram-positive, lactic acid-producing bacteria are dominant members of a healthy vaginal ecosystem, where they play a crucial role in preventing dysbiosis. Their therapeutic effect is mediated through the acidification of the local environment via lactic acid production, the secretion of inhibitory substances such as hydrogen peroxide and bacteriocins, and the competitive occupation of epithelial binding sites, which prevents the colonization and overgrowth of pathogens like Gardnerella vaginalis and Candida species. This combination is primarily investigated for the treatment and prevention of bacterial vaginosis (BV), recurrent urinary tract infections (UTIs), and other urogenital infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus gasseri + lactobacillus crispatus.